Literature DB >> 26301477

Optimising screening for cognitive dysfunction in bipolar disorder: Validation and evaluation of objective and subjective tools.

Johan Høy Jensen1, Mette Marie Støttrup1, Emilie Nayberg1, Ulla Knorr1, Henrik Ullum2, Scot E Purdon3, Lars V Kessing1, Kamilla W Miskowiak4.   

Abstract

INTRODUCTION: Cognitive impairment is common in bipolar disorder and contributes to socio-occupational difficulties. The objective was to validate and evaluate instruments to screen for and monitor cognitive impairments, and improve the understanding of the association between cognitive measures and socio-occupational capacity.
METHODS: Patients with bipolar disorder in partial or full remission (n=84) and healthy controls (n=68) were assessed with the Screen for Cognitive Impairment in Psychiatry (SCIP), Cognitive Complaints in Bipolar Disorder Rating Scale (COBRA), and established neuropsychological tests and subjective rating scales. Socio-occupational function and affective symptoms were evaluated with the Functional Assessment Short Test, and the Hamilton Depression Rating Scale 17-items and Young Mania Rating Scale, respectively. Concurrent validity of the SCIP and COBRA were assessed by correlation with established objective and subjective cognitive measures, and decision validity was determined with Receiver-Operating-Characteristic analyses. Correlations and linear regression analyses were conducted to determine the associations between objective and subjective cognitive impairment, and socio-occupational difficulties.
RESULTS: The SCIP and COBRA correlated strongly with established objective and subjective cognitive measures, respectively. The SCIP yielded higher sensitivity and specificity for detection of cognitive dysfunction than the COBRA or a combined SCIP-COBRA measure. Correlations between objective and subjective cognitive impairment were weak but both were associated with socio-occupational difficulties. LIMITATIONS: Influence of ageing was not investigated.
CONCLUSIONS: The SCIP and COBRA are valid for detection of objective and subjective cognitive impairment in bipolar disorder. Screening for cognitive dysfunction should be conducted with an objective measure like the SCIP.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Cognitive complaints; Cognitive impairment; Screening

Mesh:

Year:  2015        PMID: 26301477     DOI: 10.1016/j.jad.2015.07.039

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  18 in total

1.  Using the cognitive assessment interview to screen cognitive impairment in psychosis.

Authors:  Ana M Sánchez-Torres; María Rosa Elosúa; Ruth Lorente-Omeñaca; Lucía Moreno-Izco; Victor Peralta; Joseph Ventura; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-06-06       Impact factor: 5.270

Review 2.  Cognitive Assessment in SARS-CoV-2 Patients: A Systematic Review.

Authors:  Bruno Biagianti; Asia Di Liberto; Aiello Nicolò Edoardo; Ilaria Lisi; Letizia Nobilia; Giulia Delor de Ferrabonc; Elisa R Zanier; Nino Stocchetti; Paolo Brambilla
Journal:  Front Aging Neurosci       Date:  2022-07-01       Impact factor: 5.702

3.  Does Subjective Cognitive Function Mediate the Effect of Affective Temperaments on Functional Disability in Japanese Adults?

Authors:  Kuniyoshi Toyoshima; Takeshi Inoue; Jiro Masuya; Yota Fujimura; Shinji Higashi; Ichiro Kusumi
Journal:  Neuropsychiatr Dis Treat       Date:  2020-07-08       Impact factor: 2.570

4.  Screening for cognitive impairment in schizophrenia: Psychometric properties of the German version of the Screen for Cognitive Impairment in Psychiatry (SCIP-G).

Authors:  Gabriele Sachs; Iris Lasser; Scot E Purdon; Andreas Erfurth
Journal:  Schizophr Res Cogn       Date:  2021-05-12

5.  Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial.

Authors:  Jeff Zarp Petersen; Lejla Sjanic Schmidt; Maj Vinberg; Martin Balslev Jørgensen; Ida Hageman; Hannelore Ehrenreich; Gitte Moos Knudsen; Lars Vedel Kessing; Kamilla Woznica Miskowiak
Journal:  Trials       Date:  2018-11-06       Impact factor: 2.279

6.  Evaluation Of Subjective Cognitive Function Using The Cognitive Complaints In Bipolar Disorder Rating Assessment (COBRA) In Japanese Adults.

Authors:  Kuniyoshi Toyoshima; Takeshi Inoue; Jiro Masuya; Masahiko Ichiki; Yota Fujimura; Ichiro Kusumi
Journal:  Neuropsychiatr Dis Treat       Date:  2019-10-18       Impact factor: 2.570

7.  Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables.

Authors:  K W Miskowiak; S Johnsen; S M Sattler; S Nielsen; K Kunalan; J Rungby; T Lapperre; C M Porsberg
Journal:  Eur Neuropsychopharmacol       Date:  2021-03-29       Impact factor: 4.600

8.  Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force.

Authors:  K W Miskowiak; K E Burdick; A Martinez-Aran; C M Bonnin; C R Bowie; A F Carvalho; P Gallagher; B Lafer; C López-Jaramillo; T Sumiyoshi; R S McIntyre; A Schaffer; R J Porter; I J Torres; L N Yatham; A H Young; L V Kessing; E Vieta
Journal:  Bipolar Disord       Date:  2017-09-12       Impact factor: 6.744

9.  Effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder: study protocol for a randomized controlled trial.

Authors:  Caroline V Ott; Maj Vinberg; Christopher R Bowie; Ellen Margrethe Christensen; Gitte M Knudsen; Lars V Kessing; Kamilla W Miskowiak
Journal:  Trials       Date:  2018-09-12       Impact factor: 2.279

10.  Subjective Cognitive Impairment in 55-65-Year-Old Adults Is Associated with Negative Affective Symptoms, Neuroticism, and Poor Quality of Life.

Authors:  Amy Jenkins; Jeremy J Tree; Ian M Thornton; Andrea Tales
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.